$2.58 EPS Expected for MacroGenics Inc (MGNX) This Quarter
Equities research analysts expect MacroGenics Inc (NASDAQ:MGNX) to post earnings per share of $2.58 for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for MacroGenics’ earnings. The highest EPS estimate is $2.99 and the lowest is $2.29. MacroGenics posted earnings per share of ($1.00) in the same quarter last year, which suggests a positive year-over-year growth rate of 358%. The company is scheduled to issue its next quarterly earnings report on Tuesday, February 27th.
According to Zacks, analysts expect that MacroGenics will report full year earnings of ($0.70) per share for the current fiscal year, with EPS estimates ranging from ($0.94) to ($0.43). For the next year, analysts anticipate that the company will post earnings of ($5.02) per share, with EPS estimates ranging from ($5.69) to ($4.44). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover MacroGenics.
MacroGenics (NASDAQ:MGNX) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.09) by ($0.19). The business had revenue of $1.70 million during the quarter, compared to analysts’ expectations of $5.50 million. MacroGenics had a negative return on equity of 69.31% and a negative net margin of 1,526.55%. The firm’s revenue was down 48.5% compared to the same quarter last year. During the same period last year, the company earned ($0.97) earnings per share.
In other news, SVP Eric Blasius Risser sold 3,000 shares of the company’s stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $22.50, for a total transaction of $67,500.00. Following the transaction, the senior vice president now owns 12,100 shares in the company, valued at $272,250. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Jon Marc Wigginton sold 5,000 shares of the company’s stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $20.00, for a total transaction of $100,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 13,000 shares of company stock worth $267,500. Corporate insiders own 8.30% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Legal & General Group Plc increased its holdings in shares of MacroGenics by 4.3% during the second quarter. Legal & General Group Plc now owns 7,925 shares of the biopharmaceutical company’s stock valued at $138,000 after acquiring an additional 328 shares in the last quarter. Parametric Portfolio Associates LLC acquired a new position in shares of MacroGenics during the second quarter valued at about $203,000. Teacher Retirement System of Texas acquired a new position in shares of MacroGenics during the fourth quarter valued at about $225,000. Virtu KCG Holdings LLC acquired a new position in shares of MacroGenics during the second quarter valued at about $232,000. Finally, Private Capital Advisors Inc. acquired a new position in shares of MacroGenics during the fourth quarter valued at about $332,000. Hedge funds and other institutional investors own 85.53% of the company’s stock.
MacroGenics (NASDAQ:MGNX) opened at $22.66 on Thursday. MacroGenics has a fifty-two week low of $14.36 and a fifty-two week high of $23.90.
ILLEGAL ACTIVITY WARNING: “$2.58 EPS Expected for MacroGenics Inc (MGNX) This Quarter” was originally published by Watch List News and is the property of of Watch List News. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.watchlistnews.com/2-58-eps-expected-for-macrogenics-inc-mgnx-this-quarter/1859861.html.
MacroGenics Company Profile
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.